Search

Additional file 1: Figure S1. 13C and DEPT NMR spectrum tobindole A (1). Figure S2. 1H NMR spectrum of tobindole A (1). Figure S3. HSQC NMR spectrum of tobindole A (1). Figure S4. HMBC NMR spectrum of tobindole A (1). Figure S5. HRMS spectrum of tobindole A (1). Figure S6. UV spectrum of tobindole A (1). Figure S7. IR spectrum of tobindole A (1). Figure S8. 13C and DEPT NMR spectrum tobindole B (2). Figure S9. 1H NMR spectrum of tobindole B (2). Figure S10. HSQC NMR spectrum of tobindole B (2). Figure S11. HMBC NMR spectrum of tobindole B (2). Figure S12. HRMS spectrum of tobindole B (2). Figure S13. UV spectrum of tobindole B (2). Figure S14. IR spectrum of tobindole B (2). Figure S15. 13C and DEPT NMR spectrum tobindole C (3). Figure S16. 1H NMR spectrum of tobindole C (3). Figure S17. HSQC NMR spectrum of tobindole C (3). Figure S18. HMBC NMR spectrum of tobindole C (3). Figure S19. HRMS spectrum of tobindole C (3). Figure S20. UV spectrum of tobindole C (3). Figure S21. IR spectrum of tobindole C (3). Figure S22. 13C and DEPT NMR spectrum tobindole D (4). Figure S23. 1H NMR spectrum of tobindole D (4). Figure S24. HSQC NMR spectrum of tobindole D (4). Figure S25. HMBC NMR spectrum of tobindole D (4). Figure S26. HRMS spectrum of tobindole D (4). Figure S27. UV spectrum of tobindole D (4). Figure S28. IR spectrum of tobindole D (4). Figure S29. The antiviral inhibition rates tested by half-leaf method for ningnanmycin, compounds 1, 3 and 4. Figure S30. The protective effects of compounds 3 and 4 on TMV. Figure S31. Interactions of 1 and TMV-helicase. Figure S32. Interactions of 2 and TMV-helicase. Figure S33. Interactions of 3 and TMV-helicase. Figure S34. Polymers and ligands’ pocket of TMV-helicase. Table S1. Docking score of compounds 1-4 and original ligand in the TMV-Hel structure.